Sunesis Pharmaceuticals (SNSS) Tops Q3 EPS by 6c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q3 EPS of ($0.09), $0.06 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.09 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Movano (MOVE) Misses Q2 EPS by 195c